Stock price

Discussion in 'Acorda Therapeutics' started by anonymous, Mar 19, 2020 at 2:29 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Wud expect pfiza to require Acorda infrastructure to remain in place. They hneed our research and development skills, management team and field people.
     

  2. anonymous

    anonymous Guest

    nobody needs your infrastructure... it has been a colossal failure. Institutional knowledge?? Your CEO stated on the last investor call they miscalculated the market acceptance and revised guidance. Institutional knowledge is worthless and no one will cover a 3 year employment contract for juggling monkeys.
     
  3. anonymous

    anonymous Guest


    Habib, look at the size and structure of PFE (or any other large made up M&A possibility). Now tell me how you think they need anything from ACOR?

    ask your M&A guru how companies make deals work. They certainly don’t overpay, give employment contracts, keep all the overhead and do stock splits.

    they buy, then they gut costs.

    the problem you have is that the only thing anyone “may” be interested in is an on market asset to fill a revenue gap. No one would buy the whole company. There simply is nothing there. It will be a near impossible task to justify buying Inbrija given its weak performance and the cost and time needed to improve it.

    There are maybe three companies that make sense. Adamas, Supernus and Lundbeck. Only one has shown a willingness to overpay for a product that they should have walked away from.

    either way, everyone will be gone.

    the smart thing for any interested party is to let ACOR go bankrupt and pick up Inbrija at the fire sale from the bank.
     
  4. anonymous

    anonymous Guest

    I would add Acadia to that list. And Neurocrine. They could possibly pay for a product acquisition but not a company buyout.
    In all reality someone will aquire Inbrija AFTER Acorda has laid everyone off and is just selling assets to repay debt. The same way Acorda bought Qutenza. And since the product has been on the market for a while and it’s known what it’s sales trajectory is like, it will be a very minimal amount paid.
     
  5. anonymous

    anonymous Guest

    Talk of Acorda selling asset is ridickulus and only serve to scare off potential suiters. As well current stay home order will delay any m&a activity until most likely Q3 when rebound hopefull in full swing. Lets stop the hypoventilating, calm down and let things work out. Everyone stay healthy and well.
     
  6. anonymous

    anonymous Guest

    sounds like an Acorda plan... you will be delisted from NASDQ by end of Q3
     
  7. anonymous

    anonymous Guest

    SOON knows
    SOON enough you will known
     
  8. anonymous

    anonymous Guest

    What abt dear Dr cohen? New position in the pfizer?
     
  9. anonymous

    anonymous Guest

    Pfizer eliminated the head of incompetence position years ago.
     
  10. anonymous

    anonymous Guest

    Senior VP of R and D, that's a no braner.
     
  11. anonymous

    anonymous Guest

    Name 1 drug he’s developed. He bought zanaflex already approved. Bought Ampyra and failed 2 times with the FDA. Took 3 attempts to get approved. Bought Qutenza which was a monumental failure. Spent 525 million on Inbrija which has sold about 40-50 million? Bought Biotie and had to close the entire company because the trial failed. Ampyra for stroke failed. Ampyra for spinal injury failed. Plumiaz failed. Heart drug failed. Should I go on?
     
  12. anonymous

    anonymous Guest


    inbrija is a $1billion drug. Pfizer knows that. Dr Cohen recognized as the industry icon inhaled LD. Also rumored Nobel candidate in 2019. This justifies a senior VP of R&D position.
    ampyra issues due to incompetence of staff.

    bashing Dr Cohen only shows your bias!
     
  13. anonymous

    anonymous Guest

    Habib, Inbrija is barely a $45 million drug. Pfizer is well aware of that, as is the rest of the industry.

    I’m pretty sure the next Nobel in medicine will have to do with those combating the Wuhan virus vs those tweeting their objections to the acts of others. Unless the Nobel committee opens a category for keyboard warrior, I don’t think he is in the mix.

    give it a rest already. There is no PFE deal and everyone is well aware of that.

    should any smaller tier player take the risk, the proceeds will only go to cover debt anyway.

    it’s kind of pathetic after all your prognostications of global dominance for a me-too, overpriced product that you are now praying for an acquisition to cover your failure.
     
  14. anonymous

    anonymous Guest

    The Habib worshiper makes a good point - a major pharma deal is needed to give Inbrija enough gas in the tank to break $1 Billion. Dr Cohen has made a tremendous impact maximizing the smaller Acorda platform. Big Pharma is set to run and build out the major brand he created.
     
  15. anonymous

    anonymous Guest

    His pompousness took over. The guy is an egomaniac who lacks business skills. Nothing was ever launched at this company.
     
  16. anonymous

    anonymous Guest

    Greatness is sometimes misconstrued as pompousness. Such is the case with our dear Dr Cohen. Yes PFE will morph Inbrija into a $1billion juggernaut ! We will all prosper as never be4. Dr Cohen and his mensa braintrust from Acorda - only the best - will send and this gem
     
  17. anonymous

    anonymous Guest

    Habib, sometimes narcissists are simply the D-bags they appear to be.

    The long list of failures have been highlighted. The stock price is plainly and painfully visible to all.

    if you want to sit under your velvet, black light picture of RC and gush, so be it. The rest of the industry laughs at him and his hype.

    if PFE or anyone else thought Inbrija had promis, they would have made an offer before launch (you remember that wasted year between when it should have been approved and when it finally was).

    The days of Lipitor are long gone. Even mighty Pfizer can’t manufacture a market for this drug, which is palliative at best. Why would someone sign up to push a product that you have to give away 50-60% to get an Rx filled?

    happy bankruptcy!
     
  18. anonymous

    anonymous Guest

    Lol... break $1B.... you have a $45m market cap, which is double your annual inbrija NET sales. The only thing you will break, are the current employees still sticking around this place listening to empty promises and propaganda.
     
  19. anonymous

    anonymous Guest

    we are sticking around becuz we believe in Dr Cohen and the leadership. There is imminent prosperity when we team up with the pfiza and help them by share our pipeline and Inbrija market.
     
  20. anonymous

    anonymous Guest

    Habib,

    the “market” for Inbrija is a rounding error to Pfizer.

    employees are so far underwater on their shares that any purchase won’t change that. There is no prosperity except for your hair dyed Demi-god.

    as for a pipeline.......you are way late to the party for migraine and have no data to entice anyone or the money to generate it.

    ACOR is basically on life support with a DNR order.